Safety and Pharmacokinetic Characteristics of DKF-313
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, single-dose, 2-treatment, 2-way, 2-period crossover study
to evaluate the safety and the pharmacokinetic characteristics of DKF-313 (dutasteride and
tadalafil) in healthy male volunteers.